Endeavor Biomedicines vs BioNTech
Side-by-side comparison of AI visibility scores, market position, and capabilities
Endeavor Biomedicines is a Cambridge-based clinical-stage biotech targeting drivers of fibrosis and oncology with precision small molecules; raised $450M in a 2024 Series B led by Arch Venture Partners and GV;
About
Endeavor Biomedicines is a clinical-stage biotechnology company founded in 2022 and headquartered in Cambridge, Massachusetts, that is developing precision small-molecule medicines targeting the molecular drivers of fibrotic diseases and cancer. The company's scientific focus is on identifying and inhibiting protein targets that are specifically activated in disease states — particularly in idiopathic pulmonary fibrosis (IPF), a fatal scarring lung disease, and solid tumor oncology. Endeavor's platform emphasizes structural biology and medicinal chemistry to design compounds with high selectivity for disease-driving targets, minimizing off-target effects that have limited the tolerability of earlier investigational drugs. The company is led by CEO Tomas Kiselak and supported by a scientific advisory board of leading experts in fibrosis and cancer biology.
German mRNA pioneer co-developed COVID-19 vaccine with Pfizer; 20+ clinical programs in oncology and infectious disease;
About
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneered individualized neoantigen-specific immunotherapy and mRNA-based therapeutic approaches before co-developing the world's first authorized mRNA vaccine with Pfizer during the COVID-19 pandemic.\n\nBioNTech's pipeline spans over 20 clinical programs in oncology, infectious disease, and autoimmune conditions. Key assets include BNT111, an mRNA cancer vaccine for melanoma evaluated in combination with Regeneron's cemiplimab, as well as a suite of CAR-T, bispecific antibody, and mRNA-encoded cytokine programs. The company manufactures mRNA therapies at scale through its BioNTainer modular facilities deployable to emerging markets.\n\nBioNTech generated approximately €2.4 billion in revenue in 2024 and holds a robust cash position exceeding €17 billion, enabling sustained R&D investment. The company is recognized as one of the most pivotal biotech success stories of the 21st century, combining deep immunology science with scalable mRNA manufacturing to pursue a world where cancer is a manageable disease.
Key Details
Capabilities & Ecosystem
Also Compare
Endeavor Biomedicines vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.